Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
Monday's data sharpened the oral GLP-1 competitive map. Lilly's Foundayo (orforglipron) leads with a Phase 3 head-to-head win over oral semaglutide and a Q2 FDA filing pending. Structure's aleniglipron sits closest, with 16.3% Phase 2b weight loss and Nature Medicine publication on Friday. AstraZeneca's elecoglipron just cleared Phase 2b. Chinese entrants Hengrui-Kailera (ribupatide, HRS-7535) added Phase 2 and 3 readouts. Novo's Wegovy pill remains the only currently-approved oral, but the next-wave field is now broad and head-to-head data are arriving fast.
Genentech confirmed at its Monday investor event that the planned Phase 2 multi-arm fixed-dose combination of petrelintide (amylin analog) and enicepatide (GLP-1/GIP) starts mid-2026. The setup mirrors Novo's CagriSema and Lilly's Mounjaro-plus-amylin work, with Roche aiming for the same dual-mechanism economics that produced REIMAGINE 2's head-to-head win this week. Roche projected $9 billion in peak annual sales for the combined obesity pipeline at its Q1 print.
A Medscape ADA wrap on June 8 framed the post-GLP-1 era taking shape across the meeting: amylin analogs (petrelintide, cagrilintide, eloralintide) targeting GI-intolerance, triagonists (retatrutide), antibody-peptide conjugates (Amgen's maridebart cafraglutide/MariTide), and preclinical acceleration through AI peptide-design platforms. Each angle aims at the population gap that current GLP-1 monotherapy leaves: the patients who quit for tolerability, the ones who plateau, and the ones who need additional metabolic effects beyond appetite.
The 86th ADA Scientific Sessions wrapped Monday June 8 after presenting Phase 3 retatrutide TRIUMPH-1/TRANSCEND-T2D-1, CagriSema REIMAGINE 1/2/3, Foundayo ACHIEVE 1-5, survodutide SYNCHRONIZE-1, petrelintide ZUPREME-1, enicepatide CT388-103, elecoglipron VISTA/SOLSTICE, mazdutide GLORY-2/DREAMS-3, zenagamtide Phase 2, plus the inaugural ADA Standards of Care in Overweight and Obesity. The next inflection points: the July 23-24 PCAC peptide-compounding meeting, August 28 ITM-11 PDUFA in NETs, and the Foundayo T2D filing in Q2.
Novo Nordisk hosted its R&D investor event in New Orleans on Sunday June 7, the same day as the CagriSema and zenagamtide readouts. The pipeline conversation centered on the combination strategy that pairs CagriSema and zenagamtide with the Wegovy injection and Wegovy pill, plus IcoSema and the FGF21 analog efruxifermin in MASH. Across 40 ADA abstracts, the company is reframing itself from a single-product GLP-1 leader to a multi-mechanism cardiometabolic pipeline.
Beyond TRIUMPH-1 and TRANSCEND-T2D-1, Lilly confirmed at ADA that seven additional Phase 3 retatrutide readouts span obesity, type 2 diabetes, osteoarthritis, obstructive sleep apnea, chronic low-back pain, metabolic dysfunction-associated steatotic liver disease (MASLD), and the cardiometabolic-outcomes program. The MASLD readout is on track for H1 2027, and TRIUMPH-OUTCOMES (cardiovascular events in a 10,000-patient population) anchors the late-2027 timeline.
Genentech, Roche's US arm, will present detailed Phase 2 ZUPREME-1 data for the amylin analog petrelintide and Phase 2 CT388-103 data for the GLP-1/GIP agonist enicepatide as late-breakers at ADA 2026, with a June 8 virtual investor event. The Roche obesity package combines the two peptides as a planned fixed-dose Phase 2 combination later this year, and the company has projected $9 billion in peak annual sales for the combined pipeline.
On June 4, 2026, Alnylam Pharmaceuticals announced a partnership worth up to $2 billion with Inceptive, the AI biotech focused on programmable RNA and peptide medicines, to apply machine learning to peptide discovery. The deal is the second major back-loaded peptide-AI collaboration to land in the same week, following Regeneron's expanded Parabilis tie-up tied to Phase 3 LAG-3 setbacks.
The 86th ADA Scientific Sessions opened June 5 in New Orleans with the late-breaker embargo lifting at 6:30 p.m. CT. Saturday's June 6 Phase 3 retatrutide symposium brings full TRIUMPH-1 (28.3% mean weight loss at 80 weeks) and TRANSCEND-T2D-1 data; Monday's June 8 orforglipron ACHIEVE symposium covers head-to-head data against oral semaglutide and dapagliflozin; Roche, Novo Nordisk, and Boehringer all run investor events the same day.
Parabilis Medicines (formerly FogPharma) set terms June 4 for a Nasdaq IPO under ticker PBLS: 25 million shares at $17-19, raising about $413 million, or up to $476 million if underwriters exercise the overallotment. Proceeds fund its lead asset zolucatetide, a cell-penetrating helical peptide that blocks beta-catenin, through dose expansion and into Phase 3 for desmoid tumors, plus studies in familial adenomatous polyposis and hepatocellular carcinoma. The offering follows a $75 million Regeneron investment tied to a collaboration worth up to $2.3 billion for antibody-helicon conjugates.
The American Diabetes Association's late-breaking abstracts release Friday, June 5 at 6:30 p.m. Central, opening the meeting's data flood in New Orleans (June 5-8). Queued readouts include MetaVia's dual oxyntomodulin DA-1726 and GPR119 agonist vanoglipel, Structure's oral aleniglipron, and Hengrui and Kailera's oral incretins, alongside the Phase 3 retatrutide symposium June 6 and the orforglipron symposium June 8. Novo Nordisk holds an R&D investor event June 7.
Ahead of the ADA Scientific Sessions (June 5-8, New Orleans), Novo Nordisk previewed 40 abstracts spanning pivotal Phase 3 CagriSema in the REIMAGINE type 2 diabetes program, new mid-stage data for the amylin/GLP-1 agonist zenagamtide (the molecule previously called amycretin), and IcoSema and semaglutide analyses. Novo said its obesity and diabetes products reached 45.3 million patients by March 2026, with obesity up 58% year over year, and will host an R&D investor event June 7.
The American Diabetes Association's 86th Scientific Sessions run June 5-8, with a Phase 3 retatrutide symposium June 6 (TRIUMPH-1 and TRANSCEND-T2D-1) and a Foundayo/orforglipron symposium June 8. Beyond Lilly and Novo, the oral-incretin race fills the program: Structure's aleniglipron, Hengrui and Kailera's oral GLP-1/GIP ribupatide (up to 12.1% in Phase 2), and Boehringer/Zealand's survodutide SYNCHRONIZE-1 in obesity. More than 12,000 attendees are expected.
The American Diabetes Association's 86th Scientific Sessions open June 5-8 with the year's deepest metabolic-peptide slate. Lilly presents full TRIUMPH-1 obesity data and the first retatrutide diabetes Phase 3, TRANSCEND-T2D-1, plus the orforglipron ACHIEVE program comparing the oral GLP-1 against dapagliflozin, oral semaglutide, and placebo. Innovent's mazdutide brings GLORY-2 and the DREAMS-3 head-to-head versus semaglutide, AstraZeneca's eleglipron carries full Phase 2b data, and Lilly's GLP-1/GIP/glucagon/amylin/calcitonin quintuple agonist takes a plenary slot.
The ASCO Annual Meeting closed June 2 after a week that moved peptide and targeted-conjugate oncology from abstract to podium: Bicycle's bicyclic peptide-drug conjugate and Avacta's FAP-activated conjugate in solid tumors, Mayo's folate-receptor and BioVaxys' survivin peptide vaccines, Sapience's C/EBPβ antagonist in glioblastoma, and PSMA and lead-212 radioligands from Telix and Perspective. Attention now shifts to ADA 2026 in New Orleans and the July 23-24 PCAC compounding vote.
Eli Lilly will present full data on retatrutide, Foundayo (orforglipron), and Mounjaro at the American Diabetes Association's 86th Scientific Sessions. The triple agonist retatrutide lowered A1C by up to 2.0% and drove 16.8% weight loss, about 36.6 lbs at the 12 mg dose, over 40 weeks in its first Phase 3 diabetes trial, TRANSCEND-T2D-1. Oral Foundayo beat oral semaglutide head-to-head with 73.6% greater relative weight loss and an A1C reduction of up to 1.7% against 0.8% for dapagliflozin.
Syneron Bio, a Beijing-based macrocyclic peptide drug discovery company, closed a $150 million Series B led by an international life-science fund with co-leads Decheng Capital and CDH VGC, roughly four months after a $100 million Series A. Investors include a subsidiary of the Abu Dhabi Investment Authority, Qiming Venture Partners, and existing shareholder AstraZeneca, whose 2025 platform partnership carried $75 million upfront and near-term payments plus up to $3.4 billion in milestones. The raise reflects continued investor appetite for macrocyclic and oral peptide platforms, alongside Pinnacle Medicines' $89 million round.
BriaCell Therapeutics priced a registered direct offering of 1,449,300 common shares at $3.25 each for gross proceeds of about $4.7 million, with ThinkEquity as sole placement agent. The company plans to use proceeds for working capital, general corporate purposes, and advancing its pipeline. The raise lands days after BriaCell reported 16.6-month median overall survival for its Bria-IMT cell-based immunotherapy in heavily pretreated metastatic breast cancer at ASCO 2026.